Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 39 |
| Active Pipeline (Recruiting Now) | 14 (6) |
| Completed vs Stopped Early | 1 / 24 (61.5%) |
| Median Closed Actual Enrollment | 9 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Washington University and Siteman Cancer Center | Saint Louis, MO | 4 |
| Medical University of South Carolina | Charleston, SC | 3 |
| Hoag Memorial Hospital Presbyterian | Newport Beach, CA | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06745908 | Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Particip | Phase III | RECRUITING |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | Phase II | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the ImmunityBio Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.